SCHEDULE: RA Capital Discloses 7% Stake in Jade Biosciences

RA Capital Management and its affiliates have reported a 7.0% beneficial ownership stake in Jade Biosciences, Inc., holding 3,214,969 shares.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. collectively reported beneficial ownership of 3,214,969 shares of Jade Biosciences, Inc. common stock.
• This ownership represents 7.0% of the company's outstanding common stock.
• The calculation of the percentage is based on 32,626,730 shares outstanding as of August 8, 2025, plus an additional 13,368,164 shares issued in a private placement that closed on October 8, 2025.
• The reporting persons expressly disclaim status as a 'group' for Schedule 13G purposes.
• The shares were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The acquisition of a significant stake (7.0%) by a reputable healthcare-focused investment firm like RA Capital Management is generally a positive signal, indicating investor confidence in Jade Biosciences. While the filing itself is purely factual, the underlying action of a substantial investment suggests a favorable outlook from a sophisticated investor.

Positives

• A significant institutional investor, RA Capital Management, has taken a 7.0% stake in Jade Biosciences, indicating confidence in the company's prospects.
• The investment by a specialized healthcare fund (RA Capital Healthcare Fund, L.P.) suggests a strategic interest in the biotechnology sector.

Risks

• The reporting persons disclaim beneficial ownership of the securities for any purpose other than determining their obligations under Section 13(d) of the Act.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Jade Biosciences, Inc. or the reporting persons regarding the company's future performance or strategic direction, beyond the implicit confidence shown by the investment.

Industry Context

RA Capital Management is a prominent investment firm specializing in the healthcare and life sciences sectors. Their significant stake in Jade Biosciences suggests a belief in the company's potential within the biotechnology industry, potentially signaling future growth or development milestones for Jade Biosciences. Such an investment by a sector-focused fund can often be viewed positively by the market, as it implies thorough due diligence and strategic alignment with industry trends.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not contain information suitable for comparison to industry-specific operational or financial benchmarks or comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a 7.0% stake could instill confidence and potentially attract other investors, positively impacting share price.

Key Dates

Recommendation

The disclosure of a 7.0% beneficial ownership by RA Capital Management, a highly respected healthcare-focused investment firm, signals strong institutional confidence in Jade Biosciences. Such a significant stake by a sophisticated investor often implies thorough due diligence and a positive long-term outlook for the company, making it an attractive 'buy' for other investors.

Keywords

Jade Biosciences, RA Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Biotechnology Investment, Institutional Investor, Common Stock, Healthcare Fund